Johnson & Johnson (JNJ) Stake Lessened by Burke & Herbert Bank & Trust Co.
Burke & Herbert Bank & Trust Co. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 45,752 shares of the company’s stock after selling 1,578 shares during the period. Johnson & Johnson comprises 5.5% of Burke & Herbert Bank & Trust Co.’s holdings, making the stock its largest holding. Burke & Herbert Bank & Trust Co.’s holdings in Johnson & Johnson were worth $6,053,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. boosted its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the last quarter. Ullmann Financial Group Inc. bought a new position in Johnson & Johnson during the 1st quarter worth approximately $186,000. Taylor Wealth Management Partners raised its holdings in Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. bought a new position in Johnson & Johnson during the 1st quarter worth approximately $204,000. 65.90% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE JNJ) traded up 0.56% on Wednesday, reaching $132.84. 1,649,386 shares of the company traded hands. The company has a market capitalization of $356.54 billion, a PE ratio of 22.48 and a beta of 0.78. The stock’s 50 day moving average price is $132.27 and its 200 day moving average price is $129.78. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the company posted $1.74 earnings per share. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.
In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
A number of brokerages have recently issued reports on JNJ. Cowen and Company restated an “outperform” rating and issued a $143.00 price target on shares of Johnson & Johnson in a research report on Tuesday, June 13th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 15th. Jefferies Group LLC reiterated a “hold” rating and set a $140.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 16th. BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 5th. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $134.79.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Lessened by Burke & Herbert Bank & Trust Co.” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-lessened-by-burke-herbert-bank-trust-co/1608210.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.